News archive 2004
Stem Cell hope for degenerative disorders08 Sep 2004, PR 50/04
Pioneering work with human embryonic stem (hES) cells could speed up the development of new treatments for a range of degenerative disorders such as Parkinson’s disease and diabetes according to Dr Stephen Minger of King’s College London, speaking today (8 September) at the BA Festival of Science. And with the world’s first centralised stem cell bank the UK is well placed to be a leading player in the field of human regenerative medicine.
Stem cells are cells awaiting instructions to develop into a specific type of cell, such as a heart or liver cell. The cell takes on one of these functions in a process called differentiation. If hES cells could be differentiated into suitable cell types, stem cells might be used in cell replacement therapies for degenerative diseases, or, for instance, to repopulate the heart following damage by a heart attack.
Said Dr Minger: “There is a significant shortage of high quality human ES cell lines and few research groups have experience in the growth and manipulation of these cells. So, it is essential for the development of human stem cell technology, and the larger goal of cellular replacement therapy for human disease, that additional human cell lines are generated.”
The team at King’s College London is one of only a handful of laboratories worldwide with the expertise to create high quality hES cell lines and since generating the UK’s first hES cell line last year they have produced another two new lines.
Working with the Assisted Conception Unit at King’s College London and with local ethical approval and under licence from the Human Fertilisation and Embryology Authority, the group has been establishing high quality human ES cell lines from human embryos created during IVF treatment.
“One line was derived from an embryo screened by pre-implantation genetic diagnosis and shown to possess the most common form of Cystic Fibrosis. As the animal models for Cystic Fibrosis do not fully repeat all aspects of the disease, having a human cell line with this genetic defect will be very useful. Researchers will be able to use it to study how the mutation affects cells, screen for new treatments, and also look at gene therapy,” explained Dr Minger.
The King’s team is now attempting to derive additional cell lines encoding important human genetic disorders, such as Huntingdon’s disease, as well as continuing their work on protocols to generate therapeutically important cell populations. These include cells that could be used in the treatment of Parkinson’s disease, spinal cord damage, retinal disorders, muscular dystrophy, heart conditions, diabetes and others.
“I’m sure that the pace of research will accelerate as more scientists get involved in this field. The number of research groups using stem cells in the UK has already grown from a handful a few years ago to now about 60. The input of Government money and enlightened regulation processes will ensure that this important work continues,” added Dr Minger.
Notes to editors
1. Dr Stephen Minger is Director of the Stem Cell Biology Laboratory, King’s College London.
2. Dr Minger’s lecture “Therapeutic potential of human stem cells” will be in the session entitled “Fantastic science or Future shock - current developments in biology” on 8 September.
3. For further information on stem cell research at Kings see press releases:
(a) “First stem cell lines deposited in UK Stem Cell Bank” (19 May 2004) www.kcl.ac.uk/phpnews/wmview.php?ArtID=616
(b) First UK stem cell line generated at King’s (13 August 2003) www.kcl.ac.uk/phpnews/wmview.php?ArtID=420
King’s College London
King’s is one of the oldest and largest colleges of the University of London with 13,800 undergraduate students and some 5,300 postgraduates in ten schools of study. The College had 24 of its subject-areas awarded the highest rating of 5* and 5 for research quality, demonstrating excellence at an international level. King’s is in the top group of five universities for research earnings with income from grants and contracts of more than £93 million (2002-2003) and has an annual turnover of £320 million. King’s is a member of the Russell Group, a coalition of the UK’s major research-based universities.
BA (British Association for the Advancement of Science)
The BA is the UK's nationwide, open membership organisation dedicated to connecting science with people, so that science and its applications become accessible to all. The BA aims to promote openness about science in society and to engage and inspire people directly with science and technology and their implications.
The BA Festival of Science
The BA Festival of Science is one of the UK's biggest science festivals. It attracts 400 of the best scientists and science communicators from home and abroad who reveal the latest developments in research to a general audience. The BA Festival of Science 2004 will take place at the University of Exeter from 6 - 10 September 2004, and throughout the city from 4 - 11 September. The BA Festival 2004 is supported by the South West of England Regional Development Agency. For further information, visit www.the-ba.net/festivalofscience
BA Festival Press Office. Tel 01392-263610.
Public Relations Department
Tel: 020 7848 3202
King's student reports on tsunami disaster
King’s consortium wins inaugural EU award
King's historian wins transatlantic book prize
Hope for spinal cord injuries
King’s ranked as world leader in science
Expert warns of self-medicating with herbal medicines
Double Silver Olympic success
Londonair - New London Air Quality Network Internet Pages
Mathematicians declare The Shining perfect scary movie
Development of new rheumatoid arthritis
This information is provided by the Public Relations Department
Tel: 020-7848 3202 Fax: 020-7848 3739 Email: firstname.lastname@example.org